Merck KGaA boasts five-pronged innovation assault

22 November 2021

German life sciences major Merck KGaA’s (MRK: DE) Healthcare unit has provided an update on its innovative pipeline.

The pipeline’s focus is on five mid- to late-stage assets with first-in-class or best-in-class potential, which the company is confident will help to deliver significant long-term growth.

One of the most exciting of these assets is evobrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi) with a new mechanism of action for the treatment of patients with relapsing multiple sclerosis (RMS) that has the potential to change the standard of care. There is comprehensive Phase II data to support its best-in-class potential.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK